947248-52-4

Usage

Uses

Used in Pharmaceutical Industry:
6-BROMO-IMIDAZO[1,2-A]PYRIDIN-2-AMINE is used as an intermediate in the synthesis of various pharmaceutical compounds for its potential to contribute to the development of new drugs with diverse therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 6-BROMO-IMIDAZO[1,2-A]PYRIDIN-2-AMINE is utilized as an intermediate in the production of agrochemicals, potentially enhancing crop protection and management strategies.
Used in Chemical Research:
6-BROMO-IMIDAZO[1,2-A]PYRIDIN-2-AMINE serves as a building block in chemical research for the preparation of heterocyclic compounds, which may exhibit a range of biological activities beneficial for various applications.
Used in Medicinal Chemistry:
6-BROMO-IMIDAZO[1,2-A]PYRIDIN-2-AMINE is used in medicinal chemistry for its potential anticancer properties, as it may contribute to the discovery of novel therapeutic agents against cancer.
Used in Antiviral Research:
6-BROMO-IMIDAZO[1,2-A]PYRIDIN-2-AMINE is also utilized in antiviral research, given its potential to develop into effective antiviral agents, offering new treatment options for viral infections.

InChI:InChI=1/C7H6BrN3/c8-5-1-2-7-10-6(9)4-11(7)3-5/h1-4H,9H2

Upstream product

• 504413-35-8 N-(6-bromoimidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide 
• 207801-52-3 N-(5-bromopyridin-2-yl)-4-methylbenzenesulfonamide 
• 1072-97-5 5-bromo-2-pyridylamine 
• 937014-94-3 (Z)-2-(5-bromo-2-(tosylimino)pyridin-1(2H)-yl)acetamide 

Downstream Products

• 1162680-84-3 N-(6-bromoimidazo[1,2-a]pyridin-2-yl)acetamide 
• 1162680-37-6 N-(5-(2-aminoimidazo[1,2-a]pyridin-6-yl)-2-chloropyridin-3-yl)-4-fluorobenzenesulfonamide 
• 947249-08-3 N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridine-2-yl)acetamide 
• 1005775-52-9 4-tert-butyl-N-(6-bromoimidazo[1,2-a]pyridin-2-yl)benzamide 
• 1005775-61-0 4-tert-butyl-N-[6-(pyridin-3-yl)imidazo[1,2-a]pyridin-2-yl]benzamide 
• 1005775-72-3 4-tert-butyl-N-[6-phenylimidazo[1,2-a]pyridin-2-yl]benzamide 
• 947248-55-7 (6-bromo-imidazo[1,2-a]pyridin-2-yl)-carbamic acid phenyl ester 

Relevant academic research and scientific papers

HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME

The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosis. Formula (I) i

HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF

The present disclosure provides heteroaryl compounds of formulas (I), (Ia) and (Ib), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosi

FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE

The invention relates to compounds of formula (I) for the regulation of phosphoinositides 3-kinases activity and related diseases.

Inhibitors of PI3 kinase

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof, that inhibit phosphoinositide 3-kinase; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds.

BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS

Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE

Phosphatidylinositol (PI) 3 kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceuticall